This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Laman, J D Articles by Günthert, U Search for Related Content PubMed PubMed Citation Articles by Laman, J D Articles by Günthert, U Social Bookmarking                         What's this?

Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands, Department of Immunology, Erasmus University, Rotterdam, The Netherlands

C BM Maassen

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands

M M Schellekens

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands

L Visser

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands

M Kap

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands

E de Jong

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands

M van Puijenbroek

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands, Basel Institute for Immunology, Grenzacher Str. 487, CH-4005 Basel, Switzerland

M JB van Stipdonk

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands

M van Meurs

Division of Immunological and Infectious Diseases, TNO Prevention and Health (TNO-PG), PO Box 2215, 2301 CE Leiden, The Netherlands

C Schwärzler

Basel Institute for Immunology, Grenzacher Str. 487, CH-4005 Basel, Switzerland

U Günthert

Basel Institute for Immunology, Grenzacher Str. 487, CH-4005 Basel, Switzerland

Interactions between mononuclear cells are required for the formation of inflammatory infiltrates in the CNS and the activation of cellular effector functions provoking demyelination in MS. Membrane-expressed costimulatory molecules are crucial to such interactions. We therefore investigated whether two costimulatory molecules, CD40L (CD154, expressed on activated CD4-possible T cells) and selected CD44-variant isoforms (expressed on activated CD4-positive T cells), are targets for immunotherapy in MS. The model of experimental autoimmune encephalomyelitis (EAE) induced in SJL-mice by immunization with a peptide derived from the proteolipid protein (PLP139-151) was optimized to address these questions. A previous observation that anti-CD40L (CD154) monoclonal antibodies can effectively prevent EAE in this model was confirmed, and extended by demonstrating that CD40 is expressed by cells of the monocytic lineage infiltrating the spinal cord. In vivo treatment with antibody against the standard isoform of CD44 (CD44s or CD44H) did not affect disease burden. In contrast, combined treatment with antibodies against the isoforms CD44v6, v7 and v10, which are thought to be involved in inflammatory processes, reduced the disease burden considerably. In addition, CD44v10- expressing cells were detected in the spinal cord. These data support the idea that CD40-CD40L interactions form a target for immunotherapy of MS, and indicate that cells expressing CD44v6, v7 and/or v10-containing isoforms have such potential as well.

Key Words: accessory molecules • blood-brain barrier • central nervous system (CNS) costimulation • immunotherapy • immunohistochemistry • multiple sclerosis • CD44 variant isoforms

Multiple Sclerosis, Vol. 4, No. 3, 147-153 (1998)
DOI: 10.1177/135245859800400312


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. E. Baranzini, C. C. A. Bernard, and J. R. Oksenberg Modular Transcriptional Activity Characterizes the Initiation and Progression of Autoimmune Encephalomyelitis J. Immunol., June 1, 2005; 174(11): 7412 - 7422. [Abstract] [Full Text] [PDF]

				B. M. Wittig, B. Johansson, M. Zoller, C. Schwarzler, and U. Gunthert Abrogation of Experimental Colitis Correlates with Increased Apoptosis in Mice Deficient for Cd44 Variant Exon 7 (Cd44v7) J. Exp. Med., June 19, 2000; 191(12): 2053 - 2064. [Abstract] [Full Text] [PDF]

				P. Drillenburg and S. T. Pals Cell adhesion receptors in lymphoma dissemination Blood, March 15, 2000; 95(6): 1900 - 1910. [Abstract] [Full Text] [PDF]